These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26378999)

  • 21. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment.
    Grande C; Villanueva MJ; Huidobro G; Casal J
    Clin Transl Oncol; 2007 Sep; 9(9):578-81. PubMed ID: 17921105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe interstitial pneumonitis associated with docetaxel administration.
    Read WL; Mortimer JE; Picus J
    Cancer; 2002 Feb; 94(3):847-53. PubMed ID: 11857321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal hypersensitivity pneumonitis associated with docetaxel.
    Gurram MK; Pulivarthi S; McGary CT
    Tumori; 2013; 99(3):e100-3. PubMed ID: 24158075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel-induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocarcinoma of the lung.
    Taj A
    Hematol Oncol Stem Cell Ther; 2013; 6(3-4):117-9. PubMed ID: 24096092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
    Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
    Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel and interstitial pulmonary injury.
    Merad M; Le Cesne A; Baldeyrou P; Mesurolle B; Le Chevalier T
    Ann Oncol; 1997 Feb; 8(2):191-4. PubMed ID: 9093730
    [No Abstract]   [Full Text] [Related]  

  • 30. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
    Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
    Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Life-threatening interstitial lung disease associated with trastuzumab: case report.
    Pepels MJ; Boomars KA; van Kimmenade R; Hupperets PS
    Breast Cancer Res Treat; 2009 Feb; 113(3):609-12. PubMed ID: 18343993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cyclophosphamide-induced interstitial pneumopathy. Course data of bronchoalveolar lavage apropos of a case and review of the literature].
    Cuguillière A; Bérard H; N'Guyen G; Miltgen J; Martet G; Eskandari J; Bonnet D
    Rev Pneumol Clin; 1999 Apr; 55(2):100-4. PubMed ID: 10418054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer.
    Swayampakula AK; Alkhouri N; Haut MW; Abraham J
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):985-7; discussion 987-8. PubMed ID: 18277960
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.
    Yang L; Zhang XC; Yu SF; Zhu HQ; Hu AP; Chen J; Shen P
    BMC Cancer; 2015 Nov; 15():917. PubMed ID: 26582454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
    Hatam N; Ahmadloo N; Ahmad Kia Daliri A; Bastani P; Askarian M
    Arch Gynecol Obstet; 2011 Jul; 284(1):215-20. PubMed ID: 20740365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
    O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
    Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
    Brain EG; Bachelot T; Serin D; Kirscher S; Graic Y; Eymard JC; Extra JM; Combe M; Fourme E; Noguès C; Rouëssé J;
    JAMA; 2005 May; 293(19):2367-71. PubMed ID: 15900007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.